Showing 2861-2870 of 3186 results for "".
- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- Foamix Pharmaceuticals Ltd. Closes Initial Public Offeringhttps://practicaldermatology.com/news/20140924-foamix_pharmaceuticals_ltd_closes_initial_public_offering/2459104/Foamix Pharmaceuticals Ltd. Closes Initial Public Offering A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The sha
- AppForMyPatients Now Available: Personalized Apps for Aesthetic Practiceshttps://practicaldermatology.com/news/20140922-appformypatients_now_available_personalized_apps_for_aesthetic_practices/2459112/A new patent pending mobile app Nano 2.0 Business Press, LLC aims to allow dermatologists and plastic surgeons to meet the growing patient demand for mobile applications. AppForMyPatients is a software as a service (saas) platform for d
- Curcumin Nanoparticles Prevent Infections in Healing Woundshttps://practicaldermatology.com/news/20140922-curcumin_nanoparticles_prevent_infections_in_healing_wounds/2459114/Curcumin nanoparticles (curc-np) inhibit in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in dose-dependent fashion, and inhibits MRSA growth and enhances wound healing in an in vivo murine wound model, new research in the journal
- The ISDS Awards Scholarships to Young Doctors from Around the Worldhttps://practicaldermatology.com/news/20140917-the_isds_awards_scholarships_to_young_doctors_from_around_the_world/2459117/20 young doctors have been awarded generous scholarships from twenty leaders of the International Society for Dermatologic Surgery (ISDS) to attend an ISDS medical conference. This year, the scholarships were awarded to young doctors from Europe, Asia, Latin America (including Cuba), and
- FDA Approves Keytruda for Advanced Melanomahttps://practicaldermatology.com/news/20140904-fda_approves_keytruda_for_advanced_melanoma/2459129/The FDA granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the
- Novan's Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugshttps://practicaldermatology.com/news/20140820-novans_nitricil_technology_shows_efficacy_against_multidrug_resistant_superbugs/2459140/Novan Therapeutics' Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe, according to new data. The
- Syneron Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosishttps://practicaldermatology.com/news/20140815-syneron_introduces_new_fda-cleared_5mm_spot_size_for_treatment_of_onychomycosis/2459145/Syneron Medical Ltd. launched a new handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series. The introduction of this new FDA-cleared handp
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne